CRIS Current Research Information System

TAVOLARI, SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.370
AS - Asia 4.228
EU - Europa 2.616
AF - Africa 272
Continente sconosciuto - Info sul continente non disponibili 245
SA - Sud America 180
OC - Oceania 5
AN - Antartide 1
Totale 11.917
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.280
SG - Singapore 1.125
CN - Cina 1.123
VN - Vietnam 1.087
IT - Italia 518
GB - Regno Unito 452
SE - Svezia 331
DE - Germania 295
HK - Hong Kong 225
FR - Francia 174
IN - India 161
KR - Corea 144
CH - Svizzera 136
IE - Irlanda 132
BR - Brasile 114
FI - Finlandia 100
RU - Federazione Russa 99
NL - Olanda 97
BD - Bangladesh 84
UA - Ucraina 82
CI - Costa d'Avorio 63
ZA - Sudafrica 56
TG - Togo 55
JP - Giappone 53
CA - Canada 52
SC - Seychelles 52
JO - Giordania 38
BE - Belgio 34
ID - Indonesia 30
PH - Filippine 30
NG - Nigeria 28
EE - Estonia 26
BG - Bulgaria 24
AT - Austria 20
AR - Argentina 19
PL - Polonia 18
TH - Thailandia 18
TR - Turchia 16
IQ - Iraq 14
CL - Cile 13
ES - Italia 12
GR - Grecia 12
TW - Taiwan 12
EC - Ecuador 11
HR - Croazia 11
PK - Pakistan 11
SA - Arabia Saudita 11
MX - Messico 10
LT - Lituania 8
MY - Malesia 8
RO - Romania 8
UZ - Uzbekistan 8
CO - Colombia 7
IR - Iran 7
PS - Palestinian Territory 7
JM - Giamaica 6
AU - Australia 5
CR - Costa Rica 5
PE - Perù 5
PT - Portogallo 5
HN - Honduras 4
PY - Paraguay 4
TN - Tunisia 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
DK - Danimarca 3
DZ - Algeria 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
BB - Barbados 2
CZ - Repubblica Ceca 2
EG - Egitto 2
GT - Guatemala 2
HU - Ungheria 2
IL - Israele 2
LB - Libano 2
MA - Marocco 2
MT - Malta 2
NI - Nicaragua 2
NP - Nepal 2
RS - Serbia 2
SV - El Salvador 2
UG - Uganda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AO - Angola 1
AQ - Antartide 1
AZ - Azerbaigian 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
GE - Georgia 1
GF - Guiana Francese 1
GH - Ghana 1
GI - Gibilterra 1
GP - Guadalupe 1
KE - Kenya 1
Totale 11.663
Salva come PNG Salva come JPEG
Città #
Singapore 811
Ashburn 431
Chandler 379
Southend 369
Hefei 329
Dallas 300
San Jose 265
Ho Chi Minh City 258
Fairfield 246
Dong Ket 213
Hong Kong 209
Hanoi 208
Santa Clara 168
Houston 152
Bologna 141
Boardman 136
Dublin 132
Seoul 128
Beijing 125
Bern 125
Council Bluffs 120
Princeton 115
Wilmington 115
Ann Arbor 108
Woodbridge 108
New York 102
Seattle 99
Cambridge 90
Helsinki 81
Abidjan 63
Lauterbourg 62
Los Angeles 61
Lomé 55
Frankfurt am Main 47
Jacksonville 47
Tokyo 46
Milan 44
Nanjing 43
Da Nang 40
Westminster 38
Amman 36
Buffalo 36
Rome 35
Berlin 34
Bengaluru 33
Brussels 31
Haiphong 31
Padova 30
Guangzhou 28
Redondo Beach 28
Jinan 27
Redmond 26
San Diego 25
Sofia 24
Jakarta 23
Shanghai 23
São Paulo 22
London 20
Chicago 18
Medford 18
Abeokuta 17
Johannesburg 17
Phoenix 17
Shenyang 17
Toronto 17
Munich 15
Turin 15
Changsha 14
Lappeenranta 14
Mülheim 14
San Francisco 14
Zhengzhou 14
Can Tho 13
Orem 13
Quận Ba 13
The Dalles 13
Tongling 13
Biên Hòa 12
Florence 12
Hebei 12
Montreal 12
Nanchang 12
Vienna 12
Amsterdam 11
Fremont 11
Jiaxing 11
Rimini 11
Warsaw 11
Des Moines 10
Kuban 10
Nuremberg 10
Saint Petersburg 10
Atlanta 9
Denver 9
Hải Dương 9
Olalla 9
Shenzhen 9
Brooklyn 8
Bühl 8
Dearborn 8
Totale 7.643
Salva come PNG Salva come JPEG
Nome #
Adjuvant treatment in biliary tract cancer 348
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 306
Simple and dendritic cyclam derivative. Photophysical properties, effect of protonation and Zn++ coordination, preliminary screening as inhibitors of tumor cell growth 256
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations 252
Antiprotease strategy in combination with gemcitabine as a putative novel therapeutic approach for pancreatic cancer treatment 251
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. 251
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 248
Antitumoral Efficacy of Two Turmeric Extracts According to Different Extraction Methods in Hepatocellular Carcinoma Cell Lines 246
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 231
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 229
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 224
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study 222
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 221
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland 220
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 210
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 210
Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. 207
219 MiR-21 expression correlates with prognosis in extrahepatic radically resected cholangiocarcinomas treated with gemcitabine-based adjuvant chemotherapy 206
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 204
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 204
Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma 202
Angiogenesis modulation in human umbilical endothelial vein (HUVE) cells by selected polychlorobiphenyls congeners is mediated by estrogen receptor alpha (ERα) binding. 201
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 199
In Reply 196
Cholangiocarcinoma: Epidemiology and risk factors 191
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 188
Selected polychlorobiphenyls congeners bind to estrogen receptor alpha in human umbilical vascular endothelial (HUVE) cells modulating angiogenesis 186
Annellated pyrrole compounds for cancer management 185
The decrease of cell membrane fluidity by the non-steroidal anti-inflammatory drug Licofelone inhibits epidermal growth factor receptor signalling and triggers apoptosis in HCA-7 colon cancer cells. 185
Annellated pyrrole compounds for cancer management 182
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies 182
Classic versus innovative strategies for immuno-therapy in pancreatic cancer 179
Immunomodulation by 17beta-estradiol in bivalve hemocytes. 178
Decreasing Albumin mRNA Expression in Cholangiocarcinomas along the Bile Duct Tree. 175
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) to predict better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 173
Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner 172
The basal-like breast carcinoma phenotype is regulated by SLUG gene expression 172
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 171
Mutational Landscape of Cholangiocarcinoma According to Different Etiologies: A Review 170
Intestinal Microbiota Increases Cell Proliferation of Colonic Mucosa in Human-Flora-Associated (HFA) Mice 168
The Protease Inhibitor Gabexate Mesylate Reduces Invasiveness and Angiogenesis in Pancreatic Cancer Cell Lines, Enhancing Gemcitabine Action 168
Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link 167
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster 164
MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. 162
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? 155
Genomic And Genetic Characterization of Cholangiocarcinoma Identifies Therapeutics Targets for Tyrosine Kinase Inhibitors 147
Effect of the serine proteases inhibitor gabexate mesylate (GM) on the activity of gemcitabine (G) in cell lines of pancreatic cancer (PC) 147
Re: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. 146
IN VIVO/IN VITRO AGED FIBROBLASTS TRIGGER MALIGNANT FEATURES IN NORMAL AND CANCER STEM/PROGENITOR CELLS OF THE MAMMARY GLAND 143
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue 141
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) predicts better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 131
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 129
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. 127
Evolution of the experimental models of cholangiocarcinoma 125
Improvements in Systemic Therapies for Advanced Malignant Mesothelioma 124
Asbestos and Intrahepatic Cholangiocarcinoma 116
Carcinogenesis of Cholangiocarcinoma 115
The protease inhibitor gabexate Mesylate has antitumor effects and enhances gemcitabine action on pancreatic cancer cell lines 114
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 113
TUSC3 accelerates cancer growth and induces epithelial-mesenchymal transition by upregulating claudin-1 in non-small-cell lung cancer cells 105
Nivolumab: an investigational agent for the treatment of biliary tract cancer 103
Case Report: Long lasting response with TKI for combined hepatocellular-cholangiocarcinoma 101
null 99
Have We Found the “Holy Grail” That May Predict Response to Immunotherapy in Hepatocellular Carcinoma? 93
Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma 91
TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. 90
Circulating tumor DNA in biliary tract cancer: Current evidence and future perspectives 90
Current and novel therapeutic opportunities for systemic therapy in biliary cancer 74
Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma 36
Totale 11.917
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.211
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.211
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.043 0 35 63 83 75 39 26 57 109 95 234 227
2022/20231.586 166 232 91 186 99 108 31 99 250 41 103 180
2023/2024422 54 59 22 34 34 97 14 25 10 31 15 27
2024/20251.666 70 209 163 122 199 82 112 51 30 139 133 356
2025/20264.778 430 558 586 341 427 226 520 158 765 339 208 220
2026/2027236 100 136 0 0 0 0 0 0 0 0 0 0
Totale 11.917